Prothena Corp. Plc is an innovative pharmaceutical company based in Ireland. With an ESG risk rating score of 23.2, the company is classified as having a medium risk. Prothena Corp PLC specializes in addressing protein dysregulation and developing investigational therapeutics to combat rare neurodegenerative and peripheral amyloid diseases. Their clinical pipeline includes antibody-based product candidates targeting various conditions such as Amyloid Light-chain (AL) amyloidosis, Parkinson's disease, inflammatory diseases like psoriasis and psoriatic arthritis, and ATTR amyloidosis.